Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
CJEM
|
March 31, 2026
Teaching resuscitation of critically ill patients to medical learners in the clinical setting - A scoping review
Ann-Sophie Turcotte, Adam Szulewski, Sandra McKeown, et al.
European Journal of Haematology
|
March 31, 2016
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease
Lalit Saini, Joseph Brandwein, Robert Turner, et al.
Leukemia Research
|
October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
Heather A Leitch, Rena Buckstein, Nancy Zhu, et al.
Leukemia Research
|
April 20, 2016
Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia
Lalit Saini, Joseph Brandwein, Robert Turner, et al.
Annals of Hematology
|
October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry
Brett L Houston, Jennifer Jayakar, Richard A Wells, et al.
British Journal of Haematology
|
March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
Rena Buckstein, Richard A Wells, Nancy Zhu, et al.
British Journal of Haematology
|
June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study
Irina Amitai, Michelle Geddes, Nancy Zhu, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
British Journal of Haematology
|
July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A Leitch, Ambica Parmar, Richard A Wells, et al.
Haematologica
|
August 18, 2022
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
Jennifer Teichman, Michelle Geddes, Nancy Zhu, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
CJEM
|
March 31, 2026
Teaching resuscitation of critically ill patients to medical learners in the clinical setting - A scoping review
Ann-Sophie Turcotte, Adam Szulewski, Sandra McKeown, et al.
European Journal of Haematology
|
March 31, 2016
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease
Lalit Saini, Joseph Brandwein, Robert Turner, et al.
Leukemia Research
|
October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
Heather A Leitch, Rena Buckstein, Nancy Zhu, et al.
Leukemia Research
|
April 20, 2016
Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia
Lalit Saini, Joseph Brandwein, Robert Turner, et al.
Annals of Hematology
|
October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry
Brett L Houston, Jennifer Jayakar, Richard A Wells, et al.
British Journal of Haematology
|
March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
Rena Buckstein, Richard A Wells, Nancy Zhu, et al.
British Journal of Haematology
|
June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study
Irina Amitai, Michelle Geddes, Nancy Zhu, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
British Journal of Haematology
|
July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A Leitch, Ambica Parmar, Richard A Wells, et al.
Haematologica
|
August 18, 2022
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
Jennifer Teichman, Michelle Geddes, Nancy Zhu, et al.
Page
of 3